Terms: = Prostate cancer AND SDC4, ENSG00000124145, 6385, P31431, SYND4, MGC22217 AND Treatment
3 results:
1. Comparison of treatment costs for primary localized prostate cancer in Austria and Vienna: an economic analysis.
Moll M; Goldner G
Front Public Health; 2023; 11():1016860. PubMed ID: 37325333
[TBL] [Abstract] [Full Text] [Related]
2. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract] [Full Text] [Related]
3. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer.
Zaorsky NG; Den RB; Doyle LA; Dicker AP; Hurwitz MD
Expert Rev Med Devices; 2013 Nov; 10(6):751-63. PubMed ID: 24195459
[TBL] [Abstract] [Full Text] [Related]
